
Julian Harrison
Stock Analyst at BTIG
(4.95)
# 118
Out of 5,184 analysts
531
Total ratings
44.9%
Success rate
36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Maintained: Buy | $77 | $15.07 | +410.95% | 21 | Nov 16, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $70 → $87 | $44.40 | +95.95% | 50 | Nov 11, 2026 | |
| MAZE Maze Therapeutics | Maintained: Buy | $46 | $34.19 | +34.54% | 9 | Nov 10, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $14 → $11 | $2.88 | +281.94% | 10 | Nov 10, 2026 | |
| MREO Mereo BioPharma Group | Maintained: Buy | $1 | $0.283 | +253.36% | 15 | Nov 10, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $151 | $102.86 | +46.80% | 17 | Nov 10, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $41 | $11.31 | +262.51% | 32 | Nov 9, 2026 | |
| AKBA Akebia Therapeutics | Reiterated: Buy | $4 → $3 | $0.4013 | +647.57% | 16 | Nov 5, 2026 | |
| AVTX Avalo Therapeutics | Reiterated: Buy | $10 | $6.93 | +44.30% | 14 | Nov 5, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $44 | $7.53 | +484.33% | 13 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.88 | +54.64% | 19 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 | $10.29 | +210.98% | 13 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $11.53 | +160.19% | 34 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $121 | $103.86 | +16.50% | 27 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $728 → $768 | $562.02 | +36.65% | 21 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $178 | $37.26 | +377.72% | 23 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $175 | $85.73 | +104.13% | 18 | Oct 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.7287 | +1,272.31% | 8 | Aug 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.9578 | +422.03% | 9 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.4364 | +816.59% | 22 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $19.10 | +119.90% | 5 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $58 | $15.60 | +271.79% | 8 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $28.49 | n/a | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $82 | $132.04 | n/a | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $0.5468 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.36 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $46.45 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $3.90 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $6.56 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $1.19 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.0001 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $26.84 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $0.6337 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $0.8097 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $3.13 | n/a | 1 | Dec 9, 2020 |
Jade Biosciences
Nov 16, 2026
Maintained: Buy
Price Target: $77
Current: $15.07
Upside: +410.95%
Liquidia
Nov 11, 2026
Reiterated: Buy
Price Target: $70 → $87
Current: $44.40
Upside: +95.95%
Maze Therapeutics
Nov 10, 2026
Maintained: Buy
Price Target: $46
Current: $34.19
Upside: +34.54%
Ardelyx
Nov 10, 2026
Maintained: Buy
Price Target: $14 → $11
Current: $2.88
Upside: +281.94%
Mereo BioPharma Group
Nov 10, 2026
Maintained: Buy
Price Target: $1
Current: $0.283
Upside: +253.36%
Oruka Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $151
Current: $102.86
Upside: +46.80%
Cullinan Therapeutics
Nov 9, 2026
Maintained: Buy
Price Target: $41
Current: $11.31
Upside: +262.51%
Akebia Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $4 → $3
Current: $0.4013
Upside: +647.57%
Avalo Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $10
Current: $6.93
Upside: +44.30%
Cartesian Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $44
Current: $7.53
Upside: +484.33%
Nov 5, 2026
Reiterated: Buy
Price Target: $6
Current: $3.88
Upside: +54.64%
Nov 4, 2026
Reiterated: Buy
Price Target: $32
Current: $10.29
Upside: +210.98%
Nov 4, 2026
Reiterated: Buy
Price Target: $30
Current: $11.53
Upside: +160.19%
Nov 4, 2026
Reiterated: Buy
Price Target: $121
Current: $103.86
Upside: +16.50%
Nov 4, 2026
Reiterated: Buy
Price Target: $728 → $768
Current: $562.02
Upside: +36.65%
Oct 9, 2026
Reiterated: Buy
Price Target: $178
Current: $37.26
Upside: +377.72%
Oct 1, 2026
Reiterated: Buy
Price Target: $175
Current: $85.73
Upside: +104.13%
Aug 27, 2026
Reiterated: Buy
Price Target: $10
Current: $0.7287
Upside: +1,272.31%
Aug 19, 2026
Reiterated: Buy
Price Target: $5
Current: $0.9578
Upside: +422.03%
Aug 14, 2026
Reiterated: Buy
Price Target: $4
Current: $0.4364
Upside: +816.59%
Aug 5, 2026
Reiterated: Buy
Price Target: $42
Current: $19.10
Upside: +119.90%
Aug 3, 2026
Initiated Coverage: Buy
Price Target: $58
Current: $15.60
Upside: +271.79%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $28.49
Upside: n/a
Nov 3, 2025
Reiterated: Buy
Price Target: $82
Current: $132.04
Upside: n/a
Mar 31, 2025
Reiterated: Buy
Price Target: $14
Current: $0.5468
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $9.36
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $46.45
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $3.90
Upside: n/a
Nov 13, 2024
Reiterated: Buy
Price Target: $24
Current: $6.56
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $1.19
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.0001
Upside: n/a
Apr 28, 2021
Reiterated: Buy
Price Target: $12
Current: $26.84
Upside: n/a
Apr 27, 2021
Reiterated: Buy
Price Target: $29
Current: $0.6337
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $0.8097
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $3.13
Upside: n/a